1224 related articles for article (PubMed ID: 18847326)
1. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
[TBL] [Abstract][Full Text] [Related]
3. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
4. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.
Sato M; Zeng GQ; Turner CH
Endocrinology; 1997 Oct; 138(10):4330-7. PubMed ID: 9322947
[TBL] [Abstract][Full Text] [Related]
5. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.
Campbell GM; Bernhardt R; Scharnweber D; Boyd SK
Bone; 2011 Aug; 49(2):225-32. PubMed ID: 21515436
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
7. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength.
Yao W; Cheng Z; Koester KJ; Ager JW; Balooch M; Pham A; Chefo S; Busse C; Ritchie RO; Lane NE
Bone; 2007 Nov; 41(5):804-12. PubMed ID: 17825637
[TBL] [Abstract][Full Text] [Related]
8. Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats.
Wronski TJ; Ratkus AM; Thomsen JS; Vulcan Q; Mosekilde L
J Bone Miner Res; 2001 Aug; 16(8):1399-407. PubMed ID: 11499862
[TBL] [Abstract][Full Text] [Related]
9. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats.
Shahnazari M; Yao W; Dai W; Wang B; Ionova-Martin SS; Ritchie RO; Heeren D; Burghardt AJ; Nicolella DP; Kimiecik MG; Lane NE
Bone; 2010 May; 46(5):1267-74. PubMed ID: 19931661
[TBL] [Abstract][Full Text] [Related]
10. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture.
Lane NE; Yao W; Kinney JH; Modin G; Balooch M; Wronski TJ
J Bone Miner Res; 2003 Dec; 18(12):2105-15. PubMed ID: 14672345
[TBL] [Abstract][Full Text] [Related]
11. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.
Zhou H; Shen V; Dempster DW; Lindsay R
J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats.
Qi H; Li M; Wronski TJ
J Bone Miner Res; 1995 Jun; 10(6):948-55. PubMed ID: 7572319
[TBL] [Abstract][Full Text] [Related]
14. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
Yao W; Balooch G; Balooch M; Jiang Y; Nalla RK; Kinney J; Wronski TJ; Lane NE
Bone; 2006 Sep; 39(3):460-9. PubMed ID: 16713415
[TBL] [Abstract][Full Text] [Related]
16. Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents.
Shahnazari M; Yao W; Wang B; Panganiban B; Ritchie RO; Hagar Y; Lane NE
J Bone Miner Res; 2011 Mar; 26(3):569-81. PubMed ID: 20839286
[TBL] [Abstract][Full Text] [Related]
17. Effects of separate and combined therapy with growth hormone and parathyroid hormone on lumbar vertebral bone in aged ovariectomized osteopenic rats.
Wang L; Orhii PB; Banu J; Kalu DN
Bone; 2001 Feb; 28(2):202-7. PubMed ID: 11182379
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Li M; Mosekilde L; Søgaard CH; Thomsen JS; Wronski TJ
Bone; 1995 Jun; 16(6):629-35. PubMed ID: 7669439
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
Rhee Y; Won YY; Baek MH; Lim SK
J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
[TBL] [Abstract][Full Text] [Related]
20. Binge alcohol treatment increases vertebral bone loss following ovariectomy: compensation by intermittent parathyroid hormone.
Callaci JJ; Juknelis D; Patwardhan A; Wezeman FH
Alcohol Clin Exp Res; 2006 Apr; 30(4):665-72. PubMed ID: 16573585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
